[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-378602-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-378602-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","basics-epidemiology-diagnosis-and-management-of-liver-tumor-editorial","Basics, Epidemiology, Diagnosis, and Management of Liver Tumor - Editorial","","Editorial introducing the special issue “Basics, Epidemiology, Diagnosis, and Management of Liver Tumor,” emphasizing that distinguishing benign from malignant liver tumors, and selecting therapy requires correct knowledge, the newest guidelines, and attention to background liver disease and hepatic functional reserve. Summarized research highlights CCNDBP1’s tumor-suppressive mechanisms via the ATM–CHK2 DNA damage response and its link to inflammation and apoptosis in models. Reviews advances in surgical strategies, portal vein embolization, and ANN-based prediction to improve safe outcomes and optimize management of malignant liver tumors.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/basics-epidemiology-diagnosis-and-management-of-liver-tumor-editorial/378602/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/basics-epidemiology-diagnosis-and-management-of-liver-tumor-editorial/378602.png","ImageObject",300,407,{"name":42,"@type":43},"LangkahRina","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-01","2026-09-24",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What factors are emphasized for choosing appropriate treatment for liver tumors?","Question",{"text":63,"@type":64},"The text emphasizes correct understanding of tumor biology, use of the newest guidelines, and therapeutic intervention for background liver disease, with hepatic functional reserve as a limiting factor for selection.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does CCNDBP1 relate to DNA damage response in the summarized studies?",{"text":68,"@type":64},"The article describes CCNDBP1 activating the ATM–CHK2 checkpoint pathway by inhibiting EZH2 expression, influencing DNA damage signaling and downstream cellular responses such as inflammation and apoptosis.",{"name":70,"@type":61,"acceptedAnswer":71},"What role does portal vein embolization (PVE) and prediction play in surgical management?",{"text":72,"@type":64},"PVE is used to induce hepatic hypertrophy and increase functional capacity. The editorial also highlights ANN methods using preoperative CT images to predict maximum hepatic functional capacity and the possibility of hypertrophy after PVE.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},378602,1791317059,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,109,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":107,"slug":108},7,40,"healthcare",{"id":110,"doc_module":4,"doc_module_name":25,"category_name":111,"show_sort_weight":112,"slug":113},8,"Research & Report",30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":106,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":30,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":110},962090893776,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Editorial  \nBasics, Epidemiology, Diagnosis, and Management of Liver Tumor  \nHiroyuki Abe 1 and Kenya Kamimura 1,2, *  \nCitation: Abe, H.; Kamimura, K. Basics, Epidemiology, Diagnosis, and Management of Liver Tumor. J. Clin. Med. 2023, 12, 524. [https://](https://)[ ](https://)[doi.org/10.3390/jcm12020524](doi.org/10.3390/jcm12020524)  \nReceived: 23 December 2022  \nAccepted: 4 January 2023  \nPublished: 9 January 2023  \nCopyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University, 1-757 Asahimachido-ri, Chuo-ku, Niigata 9518510, Japan  \n2 Department of General Medicine, Niigata University School of Medicine, 1-757 Asahimachido-ri, Chuo-ku, Niigata 9518510, Japan  \n* Correspondence: [kenya-k@med.niigata-u.ac.jp](kenya-k@med.niigata-u.ac.jp); Tel.: +81-25-227-2207; Fax: +81-25-227-0776  \nLiver tumors include both benign (non-cancerous) and malignant (cancerous) varieties [1], and the latter tumors are further classified into tumors that originated in the liver (primary liver cancer) and tumors that spread from extrahepatic primary tumors (metastatic liver cancer) . Hepatocellular carcinoma (HCC) and cholangiocarcinoma are the two major malignant primary liver tumors [2], whereas colorectal, lung, and pancreatic cancers are the major extrahepatic primary tumors causing liver metastasis. A wide variety of therapeutic options can be applied to treat these tumors [3,4]; however, hepatic functional reserve is alimitation factor for the selection. Therefore, a correct understanding of the tumors, use of the newest guidelines, and therapeutic intervention for background liver disease are all essential for physicians to make correct diagnoses and therapeutic decisions. This special issue was launched to address these needs, seeking to provide the most current knowledge and understanding of basic and clinical information for the diagnosis and therapeutic management of liver tumors.  \nNiwa et al. have summarized the effects of cyclin D1-binding protein (CCNDBP1), which is considered to be a tumor suppressor, on HCC cell proliferation. They reported that CCNDBP1 activates ataxia telangiectasia mutated (ATM)—checkpoint kinase 2 (CHK2) pathway through the inhibition of EZH2 expression, assessing the gene expression in CCNDBP1-overexpressed cells and Ccndbp1 knockout mice. As a result, the overexpression of CCNDBP1 in HCC cells stimulated cell growth, showing resistance to chemotherapy and X-ray-induced DNA damage (“Cyclin D1 Binding Protein 1 Responds to DNA Damage through the ATM–CHK2 Pathway” by Niwa et al. [5]) .  \nHorigome et al. further clarified the involvement of the CCNDBP1-ATM-CHK2 pathway in the DNA damage response using dextran-sodium-sulfate (DSS)-induced colitis mice model. Interestingly, Ccndbp1 knockout mice ameliorated DSS-induced colitis, an effect indicated by the histological score increase, disease activity index elevation, and colon length shortening. These results are related to the distal colon-dominant Atm and Chk2 phosphorylation, an increase in TdT-mediated dUTP-biotin nick end labeling, and cleaved caspase 3-positive cells in the colon. These results suggested that Ccndbp1 contributed to activating the Atm–Chk2 pathway, in turn triggering inflammation and apoptosis of mucosal cells in the colon. (“Involvement of DNA Damage Response via the Ccndbp1-Atm-Chk2 Pathway in Mice with Dextran-Sodium-Sulfate-Induced Colitis” by Horirome et al. [6]) . Based on this progress, it is essential to evaluate CCNDBP1 expression in the human liver samples of various chronic liver diseases that cause inflammation and fibrotic changes,","cbCaiuz7rbjB7xMj","https://ap.wps.com/l/cbCaiuz7rbjB7xMj","pdf",189766,"English","# Editorial\n## Background and classification of liver tumors\n## CCNDBP1 and the ATM–CHK2 DNA damage response\n## Surgical strategies and functional reserve optimization\n## Prediction tools for post-PVE hepatic capacity\n## Surgical resection and pringle maneuver outcomes","[{\"question\":\"What factors are emphasized for choosing appropriate treatment for liver tumors?\",\"answer\":\"The text emphasizes correct understanding of tumor biology, use of the newest guidelines, and therapeutic intervention for background liver disease, with hepatic functional reserve as a limiting factor for selection.\"},{\"question\":\"How does CCNDBP1 relate to DNA damage response in the summarized studies?\",\"answer\":\"The article describes CCNDBP1 activating the ATM–CHK2 checkpoint pathway by inhibiting EZH2 expression, influencing DNA damage signaling and downstream cellular responses such as inflammation and apoptosis.\"},{\"question\":\"What role does portal vein embolization (PVE) and prediction play in surgical management?\",\"answer\":\"PVE is used to induce hepatic hypertrophy and increase functional capacity. The editorial also highlights ANN methods using preoperative CT images to predict maximum hepatic functional capacity and the possibility of hypertrophy after PVE.\"}]","Basics, Epidemiology, Diagnosis, and Management of Liver Tumor - Editorial | PDF",1790231388]